UnknownPhase 1

Oral Propanolol for Surgically Inaccessible Cavernous Malformations

United States346 participantsStarted 2018-02-07

Plain-language summary

The purpose of this study is to evaluate the role of propranolol as an alternative treatment for cavernous malformation in patients that may not be ideal candidates for surgery.

Who can participate

Age range1 Year – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Diagnosis of isolated or familial cavernous malformation syndrome:
✓. Written and informed consent obtained prior to study enrollment.
✓. Subject is able and willing to return for outpatient visits.
✓. Negative pregnancy test at time of enrollment for women and child-bearing potential.

Exclusion criteria

✕. Age less than 1 year-old.
✕. Propranolol allergy or allergy to other b-blockers.
✕. Estimated life expectancy of less than 1 year.
✕. History of severe anemia, cardiac dysfunction, or diabetes.
✕. A psychiatric or substance abuse problem that may interfere with study compliance.
✕. Pregnant and lactating women.

What they're measuring

Number of symptomatic and silent hemorrhages on MRI

Timeframe: 36 months

Trial details

NCT IDNCT03523650

SponsorUniversity of Virginia

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2019-01

View on ClinicalTrials.gov More Cavernous Malformations,Cerebral and/or Spinal trials